drugset
drugset / Trial / NCT06484985

Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

NCT06484985 ↗

Phase 1 Recruiting 78 enrolled Axter Therapeutics (Beijing) Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.

Timeline

Start
2024-09-04
Primary completion
2027-03
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AXT-1003 Unknown 2.5 mg Oral
Subject AXT-1003 Unknown 5 mg Oral
Subject AXT-1003 Unknown 10 mg Oral
Subject AXT-1003 Unknown 15 mg Oral
Subject AXT-1003 Unknown 20 mg Oral
Subject AXT-1003 Unknown 25 mg Oral
Subject AXT-1003 Unknown 30 mg Oral
Subject AXT-1003 Unknown 35 mg Oral
Subject AXT-1003 Unknown 40 mg Oral

Indications

non-Hodgkin lymphoma